The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Effect of post-discontinuation therapy (PDT) on survival in metastatic gastric-gastroesophageal junction (G-GEJ) adenocarcinoma patients from the RAINFALL trial: An exploratory analysis.
 
Kohei Shitara
Honoraria - Abbvie; Novartis; Yakult Pharmaceutical
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Lilly; Ono Pharmaceutical; Pfizer; Takeda
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Lilly (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Manish A. Shah
Research Funding - Boston Biomedical (Inst); Gilead Sciences (Inst); Lilly/ImClone (Inst); Merck (Inst); Sanofi/Regeneron (Inst)
 
Maria Di Bartolomeo
No Relationships to Disclose
 
Sara Lonardi
Consulting or Advisory Role - Amgen; Bayer
Speakers' Bureau - Lilly; Roche
Research Funding - Sanofi
 
Salah-Eddin Al-Batran
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Lilly; Merck; Roche; SERVIER
Speakers' Bureau - Celgene; Lilly; Nordic Bioscience; Roche
Research Funding - Celgene; Hospira; Lilly; Medac; Novartis; Roche Pharma AG; Vifor Pharma
 
Eric Van Cutsem
Consulting or Advisory Role - Bayer; Lilly; Roche; SERVIER
Research Funding - amgen (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); Merck KGaA (Inst); Novartis (Inst); Roche (Inst); Sanofi (Inst); SERVIER (Inst)
 
David H. Ilson
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Lilly/ImClone; Merck; Pieris Pharmaceuticals; Roche/Genentech
 
Ian Chau
Honoraria - Amgen; Gilead Sciences; Lilly; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Five Prime Therapeutics; Lilly; MSD Oncology; Roche/Genentech; Sanofi
Research Funding - Janssen-Cilag (Inst); Lilly (Inst); Merck Serono (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Lilly; Merck Serono; MSD; Sanofi
 
Maria Alsina
No Relationships to Disclose
 
Jill Lacy
Consulting or Advisory Role - Celgene; KeyQuest Health; Navigant Consulting; Sirtex Medical
Travel, Accommodations, Expenses - Lilly
 
Daisuke Takahari
Honoraria - Bristol-Myers Squibb; Chugai Pharma; Lilly; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Pharmaceutical
Consulting or Advisory Role - Chugai Pharma; Lilly; Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical
 
Naotoshi Sugimoto
Research Funding - Chugai Pharma; Daiichi Sankyo; Dainippon Sumitomo Pharma; Lilly; MSD; Ono Pharmaceutical; Taiho Pharmaceutical
 
Johanna C. Bendell
Research Funding - Abbott/AbbVie (Inst); Agios (Inst); Apexigen (Inst); ARMO BioSciences (Inst); Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celgene (Inst); Celldex (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EMD Serono (Inst); EMD Serono (Inst); Evelo Therapeutics (Inst); Five Prime Therapeutics (Inst); FORMA Therapeutics (Inst); Forty Seven (Inst); Forty Seven (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); Incyte (Inst); Ipsen (Inst); Kolltan Pharmaceuticals (Inst); Leap Therapeutics (Inst); Lilly (Inst); Macrogenics (Inst); Marshall Edwards (Inst); Merck (Inst); Merrimack (Inst); Mersana (Inst); Merus (Inst); Nektar (Inst); Novartis (Inst); Oncogenex (Inst); OncoMed (Inst); Onyx (Inst); Pieris Pharmaceuticals (Inst); Sanofi (Inst); Stem CentRx (Inst); SynDevRx (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); TG Therapeutics (Inst); Tyrogenex (Inst)
 
Zev A. Wainberg
Consulting or Advisory Role - Aduro Biotech; Array BioPharma; Bristol-Myers Squibb; Five Prime Therapeutics; Genentech; Lilly; Merck; Merck KGaA; Novartis; Sirtex Medical
Research Funding - Five Prime Therapeutics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Plexxikon (Inst)
Travel, Accommodations, Expenses - Genentech
 
Mustapha Tehfe
Honoraria - Bristol-Myers Squibb; Celgene; Ipsen; Lilly; Merck
Consulting or Advisory Role - AstraZeneca; Celgene; Ipsen; Lilly; Merck; Pfizer; Taiho Pharmaceutical
Speakers' Bureau - Celgene
Research Funding - Celgene
Travel, Accommodations, Expenses - Ipsen
 
David Raymond Ferry
Employment - Lilly
Leadership - Lilly
Stock and Other Ownership Interests - Lilly
 
Ran Wei
Employment - Lilly
 
Richard A. Walgren
Employment - Lilly
Stock and Other Ownership Interests - Lilly
Patents, Royalties, Other Intellectual Property - Patent applicant/holder, without royalties, for therapeutic applications related to ramucirumab and merestinib. (Inst)
 
Mayukh Das
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Charles S. Fuchs
Consulting or Advisory Role - Agios; Bayer; Dicerna; Entrinsic Health; Five Prime Therapeutics; Genentech/Roche; Gilead Sciences; KEW; Lilly; Merck; Merrimack; Sanofi; Taiho Pharmaceutical